Clobazam%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252528oral%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520formulation%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252529

# Clobazam (Oral Formulation) ## Overview Clobazam is a benzodiazepine derivative with anticonvulsant properties. It acts as a positive allosteric modulator of the GABA-A receptor, enhancing inhibitory neurotransmission. ## Primary Indications * Adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in patients 2 years of age and older. * Other seizure types (off-label, based on clinical judgment and local protocol). ## Adult Dosing * **Lennox-Gastaut Syndrome (LGS):** * Initiate at 5 mg twice daily. * Increase dose by 5-10 mg/day every 7 days to a target dose of 10 mg twice daily. * Maximum recommended daily dose: 20 mg twice daily (40 mg/day). * **Other Seizure Types (Off-Label):** Dosing varies widely based on seizure type, patient response, and tolerability. Consult specific protocols or guidelines. ## Pediatric Dosing * **Lennox-Gastaut Syndrome (LGS) - 2 years to less than 10 years:** * Initiate at 0.5 mg/kg/day divided into two doses. * Increase dose by 0.5 mg/kg/day every 7 days to a target dose of 1 mg/kg/day divided into two doses. * Maximum recommended daily dose: 1 mg/kg/day divided into two doses, not to exceed 5 mg twice daily (10 mg/day). * **Lennox-Gastaut Syndrome (LGS) - 10 years or older:** Dosing is the same as adult dosing (see Adult Dosing). ## Dose Adjustments * **Hepatic Impairment:** Use with caution. Dosage reduction may be necessary. No specific guidelines are established, individualize therapy. * **Renal Impairment:** Use with caution. No specific guidelines are established, individualize therapy. * **Concomitant Medications:** * **Strong CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole):** May increase clobazam levels. Consider dose reduction of clobazam. * **Strong CYP3A4 Inducers (e.g., rifampin, carbamazepine):** May decrease clobazam levels. Monitor for reduced efficacy and consider dose increase. * **CNS Depressants:** Additive sedative effects. Use with caution and consider dose reduction. * **Other Anticonvulsants:** Monitor for potential interactions affecting levels or efficacy. ## Contraindications * Known hypersensitivity to clobazam or other benzodiazepines. * Severe respiratory impairment. * Severe hepatic impairment. * Acute angle-closure glaucoma. ## Adverse Effects * **Common:** Somnolence, decreased appetite, constipation, vomiting, increased transaminases, lethargy, abnormal gait, irritability. * **Serious:** Serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), suicidal behavior or ideation, respiratory depression, dependence and withdrawal, cognitive impairment, paradoxical reactions (e.g., increased seizures, aggression), withdrawal symptoms upon discontinuation. ## Key Drug Interactions * **CNS Depressants (e.g., alcohol, opioids, other benzodiazepines, sedating antihistamines):** Potentiation of CNS depression. * **CYP3A4 Inhibitors/Inducers:** Alter clobazam metabolism (see Dose Adjustments). * **Other Anticonvulsants:** Potential for altered efficacy or increased adverse effects. Monitor levels and clinical response. * **Fluconazole:** May increase clobazam levels. ## Monitoring * **Clinical Efficacy:** Monitor seizure frequency and severity. * **Adverse Effects:** Assess for somnolence, behavioral changes, cognitive impairment, and signs of dependence/withdrawal. * **Liver Function Tests:** Particularly if using long-term or at higher doses. * **Withdrawal Symptoms:** Monitor closely during dose reduction or discontinuation. * **Suicidal Ideation/Behavior:** Screen patients regularly. ## Clinical Pearls * Clobazam is a Schedule IV controlled substance. * Due to the risk of serious skin reactions, patients should be advised to discontinue the drug and seek immediate medical attention if a rash develops. * Gradual tapering is essential to avoid withdrawal symptoms, which can include rebound seizures. * Clobazam can be taken with or without food. * Consider the risk of drug-drug interactions, especially with other CNS depressants and medications metabolized by CYP3A4. *** *Disclaimer: This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and professional guidelines before making any decisions about patient care.*